Researchers from Johns Hopkins University have teamed two powerful technologies to correct sickle cell disease. Linzhao Cheng and colleagues have deployed CRISPR/Cas-9 on iPS cells to replace the mutant beta globin gene. ACRONYMS AND

CRISPR Meets iPS: Technologies Converge to Tackle Sickle Cell Disease
Posted March 12, 2015 by